XDx, the Brisbane, CA-based maker of molecular diagnostics, said today it has entered into a multi-year agreement with Laboratory Corporation of America (NYSE: [[ticker:LH]]). Under the deal, heart transplant patients eligible for XDx’s AlloMap test can get their blood drawn for testing at participating LabCorp sites around the U.S., and LabCorp will be the preferred third-party, non-hospital provider of specimen processing in North America. Terms of the deal weren’t disclosed. CEO Pierre Cassigneul told Xconomy last year that he thinks XDx will be able to turn its first profit in 2011.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
